Inhalation Toxicology Core (ITC)
吸入毒理学核心 (ITC)
基本信息
- 批准号:10576459
- 负责人:
- 金额:$ 4.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-15 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AerosolsAgonistAirAirborne Particulate MatterAlveolarAnimalsAreaAryl Hydrocarbon ReceptorBiomedical ResearchBloodBreathingCardiopulmonaryCell Culture TechniquesCell surfaceCellsChemicalsCoculture TechniquesCollaborationsCollectionComplementComplexComplex MixturesCustomCytochrome P450DataData SetDepositionDoseDrynessEnvironmentEnvironmental ExposureEnvironmental PollutantsEpithelial CellsEpitheliumEquilibriumEquipmentExposure toFree RadicalsFunctional disorderGoalsHealthHelper-Inducer T-LymphocyteImmunologicsIn VitroInhalationInhalation ExposureInhalation ToxicologyLifeLipidsLiquid substanceLouisianaLungMeasurementMeasuresMediatingMembrane LipidsMethodologyMethodsMissionModalityModelingMolecularMorphologyMusOxidative Stress InductionParticulateParticulate MatterPatternPhysiologicalPostdoctoral FellowProductionProgram Research Project GrantsPropertyPulmonary function testsQuartzReceptor ActivationReceptor SignalingResearchResearch PersonnelResearch Project GrantsResistanceRodentRouteSamplingSuperfundSurfaceSuspensionsSystemTechniquesTimeToxic effectTrainingUniversitiesWorkaerosolizedairway epitheliumaqueouscardiopulmonary systemdesigndosimetryexperimental studyexposed human populationin vitro Modelin vivoinnovationinsightinstrumentationnoveloxidationparticleparticle exposurepneumocytepollutantpressureprogramspulmonary functionremediationrespiratoryrespiratory healthresponseultrafine particlevapor
项目摘要
Project Summary/Abstract: Inhalation Toxicology Core (ITC)
Recreating an environment representative of real-life exposure scenarios is critical for experimental studies.
Inhalation is the most representative route of human exposure to airborne particulate matter (PM). The
assessment of cardiopulmonary dysfunction induced by inhaled PM is complex and involves a variety of
factors, including the physicochemical properties of the PM in its actual exposure form and dose. Innovative,
state-of-the-art exposure techniques are essential to reliably conduct in vivo and in vitro inhalation studies.
Therefore, to complement the physicochemical characterization of the bulk particles containing environmentally
persistent free radicals (EPFRs), as determined by the Material Core (MC), the Inhalation Toxicology Core
(ITC) will generate, deliver, and characterize EPFR-aerosols for the in vivo and in vitro exposures of LSU SRP
Projects 1 and 2. The mission of the ITC is to provide the expertise, training, facilities and equipment
necessary for LSU SRP investigators to expose either mice or cell systems to aerosolized and well-
characterized EPFR-containing aerosols, as well as to assess lung function in exposed mice. This support is
highlighted through three specific activities: 1) Generating stable EPFR-aerosols under real-life environmental
exposure conditions, as well as characterizing the physicochemical properties of the inhalable aerosols in the
breathing zone of the mice for Projects 1 and 2. Since it is hypothesized that EPFR-induced cardiopulmonary
dysfunction involves induction of oxidative stress at the air-blood interface, a unique innovative advantage of
this integrated EPFR-aerosol inhalation exposure system is that it facilitates mechanistic studies by allowing
dosimetry of environmentally-relevant particles of known size distribution capable of reaching the alveolar
region. 2) Providing support for lung function testing in mice for Project 1 via invasive techniques. The ITC will
provide the equipment, for instance the flexiVent system, to assess lung function (resistance and compliance)
in mice exposed by inhalation to EPFR-aerosols. 3) Generating and characterizing EPFR-aerosols for in vitro
exposure models at the air-liquid interface (ALI) of co-cultured cells for Projects 1 and 2. The ALI environment
simulates realistic pulmonary deposition patterns and cellular dosimetry, allowing for suitable cellular and
molecular responses. Overall, the outstanding research capabilities of the ITC permits investigators to obtain
both in vivo (functional and physiological) and in vitro (cellular and molecular) results following exposures to
EPFR-aerosols under similar exposure conditions and characterization methods. Thus, allowing for elucidation
of precise EPFR-induced cardiopulmonary dysfunction mechanisms through novel complementary in vivo and
in vitro data-sets. In conclusion, the ITC is a central interdisciplinary platform, custom designed to fit the overall
goals of the Center by incorporating real-world exposure data, scenarios, and samples collected from Project 3
and characterized in collaboration with the MC, as well as providing the exposure methodology and expertise
for Projects 1 and 2.
项目摘要/摘要:吸入毒理学核心(ITC)
重建一个代表真实暴露场景的环境对于实验研究至关重要。
吸入是人类接触空气颗粒物(PM)的最具代表性的途径。这个
吸入PM所致心肺功能障碍的评估是复杂的,涉及多种
因素,包括PM在其实际暴露形式和剂量下的物理化学性质。创新,
最先进的暴露技术对于可靠地进行体内和体外吸入研究是必不可少的。
因此,为了补充环境中含有的大块颗粒的物理化学表征
持久性自由基(EPFR),由吸入毒理学核心物质核心(MC)测定
(ITC)将为LSU SRP的体内和体外暴露产生、交付和表征EPFR气雾剂
项目1和2.贸易中心的任务是提供专门知识、培训、设施和设备
路易斯安那州立大学SRP调查人员有必要将小鼠或细胞系统暴露于雾化和良好的-
对含有EPFR的气雾剂进行了表征,并评估了暴露小鼠的肺功能。这一支持是
通过三个具体活动突出:1)在真实环境下产生稳定的EPFR气溶胶
暴露条件,以及表征空气中可吸入气溶胶的物理化学性质
项目1和2的小鼠呼吸区。由于假设EPFR诱导的心肺
功能障碍涉及在空气-血液界面诱导氧化应激,这是一种独特的创新优势
这种集成的EPFR-气雾剂吸入暴露系统通过允许
已知大小分布的能够到达肺泡的环境相关颗粒物的剂量测定
区域。2)通过侵入性技术为项目一小鼠肺功能检测提供支持。国际贸易委员会将
提供设备,例如FlexiVent系统,以评估肺功能(抵抗力和顺应性)
吸入EPFR气雾剂的小鼠。3)体外EPFR气雾剂的制备和表征
项目1和项目2的共培养细胞的气液界面暴露模型。ALI环境
模拟真实的肺沉积模式和细胞剂量测定,允许适当的细胞和
分子反应。总体而言,国贸中心出色的研究能力使调查人员能够获得
暴露在体内(功能和生理)和体外(细胞和分子)的结果
EPFR-气溶胶在相似的暴露条件和表征方法下。因此,允许澄清
EPFR诱导的心肺功能障碍机制的体内和体外新互补研究
体外数据集。总而言之,ITC是一个中央跨学科平台,定制设计以适应整体
通过纳入从项目3收集的真实世界暴露数据、场景和样本来实现中心的目标
与MC合作,并提供曝光方法和专业知识
对于项目1和2。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexandra Noel其他文献
Alexandra Noel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexandra Noel', 18)}}的其他基金
Effects of nicotine salt-rich JUUL aerosols on the mouse developing lung
富含尼古丁盐的 JUUL 气雾剂对小鼠肺部发育的影响
- 批准号:
10194831 - 财政年份:2020
- 资助金额:
$ 4.34万 - 项目类别:
Cardiopulmonary effects induced by electronic-cigarette and JUUL aerosols in both in vivo and in vitro models.
电子烟和 JUUL 气雾剂在体内和体外模型中诱导的心肺效应。
- 批准号:
10367983 - 财政年份:2020
- 资助金额:
$ 4.34万 - 项目类别:
Cardiopulmonary effects induced by electronic-cigarette and JUUL aerosols in both in vivo and in vitro models.
电子烟和 JUUL 气雾剂在体内和体外模型中诱导的心肺效应。
- 批准号:
10563196 - 财政年份:2020
- 资助金额:
$ 4.34万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 4.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 4.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)